Loading...
Market
How many countries will approve gene therapy for sickle cell disease by end of 2025?
2
Resolution / Starting Odds
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
International health agency reports and country-specific healthcare announcements
Story
12-Year-Old Kendric Cromer First to Receive Approved Gene Therapy for Sickle Cell Disease
Oct 22, 2024, 12:38 AM
Gene therapy has shown promising results in treating sickle cell disease, with a significant milestone achieved recently. Kendric Cromer, a 12-year-old boy, became the first patient to receive an approved gene therapy for sickle cell disease. After spending 44 days in the hospital, he was discharged from Children’s National Hospital in Washington. Kendric expressed his relief, saying, “I thought I would have sickle cell for the rest of my life.” The therapy offers hope to the approximately 100,000 people in the U.S. who have sickle cell disease, particularly the 20,000 with the most severe cases. However, the treatment comes with challenges and costs.
View original story
Similar markets
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
<10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
>30 countries • 25%
United States • 25%
European Union • 25%
United Kingdom • 25%
Other • 25%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
0 countries • 25%
1-2 countries • 25%
3-4 countries • 25%
5 or more countries • 25%
No countries • 25%
1 to 5 countries • 25%
6 to 10 countries • 25%
More than 10 countries • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
Yes • 50%
No • 50%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
Japan • 25%
USA • 25%
EU • 25%
Other • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%